Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2021-02-11 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly states that Ipsen "a publié aujourd'hui ses résultats financiers pour l'année 2020" (published today its financial results for the year 2020). It contains detailed financial figures for the full year (2020 vs 2019), including revenue, operating margin, and EPS, and provides forward-looking guidance for 2021. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, often released before the full 10-K or IR filing. Although it contains detailed analysis, the format is that of a press release summarizing the annual performance, fitting the definition of an Earnings Release (ER) better than the comprehensive Annual Report (10-K) or the Interim Report (IR) since it covers the full fiscal year. The mention of a proposed dividend (footnote 2) and the discussion of R&D pipeline progress further support this classification as a primary results announcement. FY 2020
2021-02-11 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release from Ipsen dated February 8, 2021, announcing the presentation of new analyses from the pivotal Phase III CheckMate-9ER study regarding the combination of Cabometyx® and Opdivo® for advanced renal cell carcinoma (RCC). It details clinical efficacy data (PFS, OS, ORR) and quality of life improvements, referencing presentations at the ASCO GU Symposium. This content structure—a formal announcement of clinical trial results and data presentation schedules, often issued by pharmaceutical companies—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), and it focuses on clinical/business updates, it best fits the 'Earnings Release' category, which often includes significant operational or clinical milestones announced outside of formal quarterly reporting periods, or it could be classified as a general Regulatory Filing (RNS) if ER is too narrow. Given the focus on presenting new data/results, ER is a strong candidate, but since it's a clinical data announcement rather than financial earnings, 'Regulatory Filings' (RNS) serves as a robust general announcement category for non-standard, material corporate news, or 'Investor Presentation' (IP) if it were the presentation itself. However, this is a press release *about* the presentation. Given the options, and recognizing this is a material corporate announcement of clinical data, it aligns most closely with the nature of an Earnings Release (ER) which often encompasses major operational/clinical news, or RNS as a catch-all. Since it is a formal announcement of results, I will lean towards ER as it serves the function of communicating key performance/development indicators to the market, even if not strictly financial earnings. FY 2021
2021-02-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen, dated February 8, 2021, announcing new data from the pivotal Phase III CheckMate -9ER trial for Cabometyx® in combination with Opdivo®. It details efficacy and quality of life results, mentions presentations at the ASCO GU Symposium, and includes quotes from key personnel and background information on the drug and the disease. This format—a formal announcement of clinical trial results and associated presentations—is characteristic of an Earnings Release (ER) or a general press release related to clinical data updates. Since it is a detailed announcement of results rather than just a brief highlight summary (which would lean towards ER), and it is not a full regulatory report (like 10-K or IR), it fits best as an Earnings Release (ER) or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on presenting new clinical data and trial outcomes, ER is the most appropriate fit among the specific options, as these announcements often accompany or precede quarterly financial reporting periods, even if the primary content is clinical data. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal regulatory report (10-K, IR). It is a comprehensive announcement of results, making ER the strongest candidate over the general fallback RNS.
2021-02-08 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated February 5, 2021, announcing that Ipsen will present new data from its oncology portfolio at the ASCO GU 2021 Symposium. It details the abstracts, trial highlights (like CheckMate -9ER), and provides background information on the diseases and products. This format—an announcement of upcoming scientific presentations or data releases, often issued by a pharmaceutical company—is characteristic of an Investor Presentation (IP) or a general press release related to investor/medical affairs. Since it is not a formal regulatory filing (like 10-K, AR, or ER), and it is a detailed presentation of data and strategy for investors/medical community, 'Investor Presentation' (IP) is the most fitting category, although it is presented as a press release. It is not a simple 'Report Publication Announcement' (RPA) because it contains substantial narrative and data summaries, not just a notice that a report is available.
2021-02-05 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen, dated February 5, 2021, announcing that new data from its oncology portfolio will be presented at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU). It details specific abstracts, clinical trials (like CheckMate-9ER), and product information (Cabometyx®, Decapeptyl®). This content—announcing participation in a medical conference and presenting clinical data—is characteristic of an Investor Presentation (IP) or a general press release related to investor/medical updates. Since it is a formal announcement detailing upcoming data presentations and clinical trial results rather than a full financial report (10-K, IR) or a simple earnings highlight (ER), 'Investor Presentation' (IP) is the most fitting category, as these often overlap with scientific/clinical updates aimed at investors and the medical community. It is not a short announcement of a report publication (RPA/RNS) because the document itself contains substantial detail about the data being presented.
2021-02-05 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Executive Vice President, Gwenan White, effective March 2021. It details her new role, responsibilities, reporting structure, and background, followed by standard 'About the Company' and 'Forward Looking Statement' sections. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a transcript (CT).
2021-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.